CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
imiquimod +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00821964
NCT00821964Phase 2Completed

Phase II Study of Topical Imiquimod and Weekly Abraxane for the Treatment of Breast Cancer Cutaneous Metastases

University of Washington·interventional·Posted Jan 14, 2009·Updated Jan 2, 2018

In Brief

A Phase 2 clinical trial evaluating imiquimod, Abraxane, and 3 other interventions for Male Breast Cancer and 3 related conditions. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This phase II trial is studying the side effects of giving topical imiquimod together with Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) to see how well it works in treating patients with advanced breast cancer. Biological therapies, such as imiquimod, may stimulate the immune system to kill tumor cells. Drugs used in chemotherapy, such as Abraxane, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imiquimod together with Abraxane may kill more tumor cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 14, 2009
Enrollment StartDec 1, 2008
Primary CompletionNov 1, 2012
Study CompletionNov 29, 2012
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 17.5 years ago

Interventions

imiquimoddrug

Given topically

Abraxanedrug

Given IV

laboratory biomarker analysisother

Correlative studies

RNA analysisgenetic

Correlative studies

immunoenzyme techniqueother

Correlative studies